The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Self-citationGenomic Aberrations and Survival in Chronic Lymphocytic Leukemia
Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M., & Lichter, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432602 · Cited by 3,318
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., et al. (1999) · Blood · doi:10.1182/blood.v94.6.1840 · Cited by 2,642
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61381-5 · Cited by 1,888
Self-citationBinet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., et al. (1981) · Cancer · doi:10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v · Cited by 1,778
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M., Montserrat, E., Chiorazzi, N., et al. (2018) · Blood · doi:10.1182/blood-2017-09-806398 · Cited by 1,740
Self-citationIdelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315226 · Cited by 1,710
Self-citationIbrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Self-citationObinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., de la Serna, J., Dilhuydy, M.-S., Illmer, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313984 · Cited by 1,518
Self-citationEvolution and impact of subclonal mutations in chronic lymphocytic leukemia
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.01.019 · Cited by 1,379
Fischer, K., Bahlo, J., Fink, A. M., Goede, V., Herling, C. D., Cramer, P., Langerbeins, P., von Tresckow, J., Engelke, A., Maurer, C., et al. (2016) · Blood · doi:10.1182/blood-2015-06-651125 · Cited by 1,299
Self-citationSF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Wang, L., Lawrence, M. S., Wan, Y., Stojanov, P., Sougnez, C., Stevenson, K., Werner, L., Sivachenko, A., DeLuca, D. S., Zhang, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109016 · Cited by 1,080
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1812836 · Cited by 962
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
Self-citationVenetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A.-M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1815281 · Cited by 873
Self-citationIbrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O’Brien, S., Barrientos, J., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817073 · Cited by 749
(2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30029-8 · Cited by 672
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30262-2 · Cited by 631
Self-citationEichhorst, B., Fink, A.-M., Bahlo, J., Busch, R., Kovacs, G., Maurer, C., Lange, E., Köppler, H., Kiehl, M., Sökler, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30051-1 · Cited by 627
Self-citationHamblin, T. J., Orchard, J. A., Ibbotson, R. E., Davis, Z., Thomas, P. W., Stevenson, F. K., & Oscier, D. G. (2002) · Blood · doi:10.1182/blood.v99.3.1023 · Cited by 618
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Zenz, T., Eichhorst, B., Busch, R., Denzel, T., Häbe, S., Winkler, D., Bühler, A., Edelmann, J., Bergmann, M., Hopfinger, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8762 · Cited by 617
Self-citationMonoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
Rawstron, A. C., Bennett, F. L., O'Connor, S. J. M., Kwok, M., Fenton, J. A. L., Plummer, M., de Tute, R., Owen, R. G., Richards, S. J., Jack, A. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa075290 · Cited by 613
Self-citationMoreno, C., Greil, R., Demirkan, F., Tedeschi, A., Anz, B., Larratt, L., Simkovic, M., Samoilova, O., Novak, J., Ben-Yehuda, D., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30788-5 · Cited by 556
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Stilgenbauer, S., Schnaiter, A., Paschka, P., Zenz, T., Rossi, M., Döhner, K., Bühler, A., Böttcher, S., Ritgen, M., Kneba, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-546150 · Cited by 516
Self-citationThompson, P. A., Tam, C. S., O’Brien, S. M., Wierda, W. G., Stingo, F., Plunkett, W., Smith, S. C., Kantarjian, H. M., Freireich, E. J., & Keating, M. J. (2016) · Blood · doi:10.1182/blood-2015-09-667675 · Cited by 505
Rossi, D., Rasi, S., Spina, V., Bruscaggin, A., Monti, S., Ciardullo, C., Deambrogi, C., Khiabanian, H., Serra, R., Bertoni, F., et al. (2013) · Blood · doi:10.1182/blood-2012-09-458265 · Cited by 467
Böttcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R. M., Fingerle-Rowson, G., Fink, A. M., Bühler, A., Zenz, T., Wenger, M. K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9348 · Cited by 460
Self-citationChlorambucil in Indolent Chronic Lymphocytic Leukemia
Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., Leporrier, M., Jaubert, J., Lepeu, G., Dreyfus, B., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382104 · Cited by 447
Moreton, P., Kennedy, B., Lucas, G., Leach, M., Rassam, S. M. B., Haynes, A., Tighe, J., Oscier, D., Fegan, C., Rawstron, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.021 · Cited by 419
Self-citationO’Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., et al. (2018) · Blood · doi:10.1182/blood-2017-10-810044 · Cited by 385
Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30909-9 · Cited by 383
Ghia, P., Pluta, A., Wach, M., Lysak, D., Kozak, T., Simkovic, M., Kaplan, P., Kraychok, I., Illes, A., de la Serna, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03355 · Cited by 372
Self-citationTam, C. S., Trotman, J., Opat, S., Burger, J. A., Cull, G., Gottlieb, D., Harrup, R., Johnston, P. B., Marlton, P., Munoz, J., et al. (2019) · Blood · doi:10.1182/blood.2019001160 · Cited by 361
Al-Sawaf, O., Zhang, C., Tandon, M., Sinha, A., Fink, A.-M., Robrecht, S., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30443-5 · Cited by 337
Self-citationKater, A. P., Seymour, J. F., Hillmen, P., Eichhorst, B., Langerak, A. W., Owen, C., Verdugo, M., Wu, J., Punnoose, E. A., Jiang, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01580 · Cited by 309
Self-citationEarly-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
Ghez, D., Calleja, A., Protin, C., Baron, M., Ledoux, M.-P., Damaj, G., Dupont, M., Dreyfus, B., Ferrant, E., Herbaux, C., et al. (2018) · Blood · doi:10.1182/blood-2017-11-818286 · Cited by 307
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Pflug, N., Bahlo, J., Shanafelt, T. D., Eichhorst, B. F., Bergmann, M. A., Elter, T., Bauer, K., Malchau, G., Rabe, K. G., Stilgenbauer, S., et al. (2014) · Blood · doi:10.1182/blood-2014-02-556399 · Cited by 283
Self-citationIbrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
Hillmen, P., Rawstron, A. C., Brock, K., Muñoz-Vicente, S., Yates, F. J., Bishop, R., Boucher, R., MacDonald, D., Fegan, C., McCaig, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00894 · Cited by 272
Self-citationLong-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
Byrd, J. C., Hillmen, P., O’Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., Barr, P. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-870238 · Cited by 245
Self-citationBaliakas, P., Jeromin, S., Iskas, M., Puiggros, A., Plevova, K., Nguyen-Khac, F., Davis, Z., Rigolin, G. M., Visentin, A., Xochelli, A., et al. (2019) · Blood · doi:10.1182/blood-2018-09-873083 · Cited by 242
Self-citationGoede, V, Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L. F. C., Montillo, M., Fegan, C., Asikanius, E., Humphrey, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.14 · Cited by 237
Self-citationMato, A. R., Hill, B. T., Lamanna, N., Barr, P. M., Ujjani, C. S., Brander, D. M., Howlett, C., Skarbnik, A. P., Cheson, B. D., Zent, C. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx031 · Cited by 229
Ghielmini, M., Vitolo, U., Kimby, E., Montoto, S., Walewski, J., Pfreundschuh, M., Federico, M., Hoskin, P., McNamara, C., Caligaris-Cappio, F., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds517 · Cited by 218
Self-citationBurger, J. A., Sivina, M., Jain, N., Kim, E., Kadia, T., Estrov, Z., Nogueras-Gonzalez, G. M., Huang, X., Jorgensen, J., Li, J., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879429 · Cited by 217
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Ahn, I. E., Farooqui, M. Z. H., Tian, X., Valdez, J., Sun, C., Soto, S., Lotter, J., Housel, S., Stetler-Stevenson, M., Yuan, C. M., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820910 · Cited by 205
Self-citationMalcikova, J., Tausch, E., Rossi, D., Sutton, L. A., Soussi, T., Zenz, T., Kater, A. P., Niemann, C. U., Gonzalez, D., Davi, F., et al. (2018) · Leukemia · doi:10.1038/s41375-017-0007-7 · Cited by 204
Self-citationBiology and treatment of Richter syndrome
Rossi, D., Spina, V., & Gaidano, G. (2018) · Blood · doi:10.1182/blood-2018-01-791376 · Cited by 195
Villamor, N., Conde, L., Martínez-Trillos, A., Cazorla, M., Navarro, A., Beà, S., López, C., Colomer, D., Pinyol, M., Aymerich, M., et al. (2013) · Leukemia · doi:10.1038/leu.2012.357 · Cited by 190
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax
Anderson, M. A., Tam, C., Lew, T. E., Juneja, S., Juneja, M., Westerman, D., Wall, M., Lade, S., Gorelik, A., Huang, D. C. S., et al. (2017) · Blood · doi:10.1182/blood-2017-01-763003 · Cited by 178
Byrd, J. C., Wierda, W. G., Schuh, A., Devereux, S., Chaves, J. M., Brown, J. R., Hillmen, P., Martin, P., Awan, F. T., Stephens, D. M., et al. (2020) · Blood · doi:10.1182/blood.2018884940 · Cited by 178
Self-citationImmunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations
Rosenquist, R., Ghia, P., Hadzidimitriou, A., Sutton, L.-A., Agathangelidis, A., Baliakas, P., Darzentas, N., Giudicelli, V., Lefranc, M., Langerak, A. W., et al. (2017) · Leukemia · doi:10.1038/leu.2017.125 · Cited by 161
Self-citationAbrisqueta, P., Pereira, A., Rozmán, C., Aymerich, M., Giné, E., Moreno, C., Muntañola, A., Rozman, M., Villamor, N., Hodgson, K. E., et al. (2009) · Blood · doi:10.1182/blood-2009-04-214346 · Cited by 155
Self-citationIncidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
de Weerdt, I., Koopmans, S. M., Kater, A. P., & van Gelder, M. (2017) · Haematologica · doi:10.3324/haematol.2017.164103 · Cited by 147
Self-citationCoutre, S. E., Choi, M. Y., Furman, R. R., Eradat, H. A., Heffner, L. T., Jones, J. A., Chyla, B., Zhou, L., Agarwal, S., Waskiewicz, T., et al. (2018) · Blood · doi:10.1182/blood-2017-06-788133 · Cited by 143
Herling, C., Klaumuenzer, M., Rocha, C. K., Altmüller, J., Thiele, H., Bahlo, J., Kluth, S., Crispatzu, G., Herling, M., Schiller, J., et al. (2016) · Blood · doi:10.1182/blood-2016-01-691550 · Cited by 126
Self-citationDreger, P., Ghia, P., Schetelig, J., van Gelder, M., Kimby, E. K., Michallet, M., Moreno, C., Robak, T., Stilgenbauer, S., & Montserrat, E. (2018) · Blood · doi:10.1182/blood-2018-01-826008 · Cited by 116
Self-citationCramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Langerbeins, P., Al‐Sawaf, O., Engelke, A., Fink, A., Fischer, K., Tausch, E., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30414-5 · Cited by 113
Self-citationGribben, J. G., Bosch, F., Cymbalista, F., Geisler, C. H., Ghia, P., Hillmen, P., Moreno, C., & Stilgenbauer, S. (2018) · British Journal of Haematology · doi:10.1111/bjh.15080 · Cited by 78
Self-citationBretones, G., Alvarez, M., Arango, J. R., Rodríguez, D., Nadeu, F., Prado, M. A., Valdés‐Mas, R., Puente, D. A., Paulo, J. A., Delgado, J., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804401 · Cited by 71
TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods
Kantorová, B., Malčíková, J., Šmardová, J., Pavlová, Š., Trbušek, M., Tom, N., Plevová, K., Tichý, B., Truong, S., Divíšková, E., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2971-0 · Cited by 13
Cited by
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211582 · Cited by 489
Self-citationTam, C. S., Brown, J. R., Kahl, B. S., Ghia, P., Giannopoulos, K., Jurczak, W., Šimkovič, M., Shadman, M., Österborg, A., Laurenti, L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00293-5 · Cited by 291
Self-citationVanstapel, F. J. L. A., Orth, M., Streichert, T., Capoluongo, E. D., Oosterhuis, W. P., Çubukçu, H. C., Bernabeu-Andreu, F. A., Thelen, M., Jacobs, L. H. J., Linko, S., et al. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0045 · Cited by 45
Integrin Signaling Shaping BTK-Inhibitor Resistance
Polcik, L., Dannewitz Prosseda, S., Pozzo, F., Zucchetto, A., Gattei, V., & Hartmann, T. N. (2022) · Cells · doi:10.3390/cells11142235 · Cited by 15
Metadata
- Authors
- Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., Hallek, M., & Mey, U.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 32
- Issue
- 1
- Pages
- 23-33
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4213170825
- Cited by
- 585
- References
- 65
- FWCI
- 33.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.